Objective-To examine the pharmacological interaction of salmeterol and salbutamol and to derive an estimate of dose equivalence of salmeterol for airway and systemic effects in patients with asthma.
Introduction
Salmeterol, a new long acting 12 agonist, produces bronchodilatation for at least 12 hours in patients with asthma`3 and when given in doses of 50 pug twice daily provides more effective control of asthma symptoms than salbutamol 200 tpg four times daily.45 Whether this difference represents an important additional effect of salmeterol or is simply due to a higher relative dose is uncertain. The dose equivalence of salmeterol compared with salbutamol determined from single dose studies of acute changes in lung function has ranged from 1 to 16 -that is, doses of salmeterol from lighted by the recent experience in New Zealand, where the excess mortality associated with fenoterol79 has been attributed to marketing of a metered dose inhaler that contained a two to four times higher relative dose of fenoterol compared with salbutamol."°I t is recommended that salmeterol be taken regularly twice daily and that a shorter acting P2 agonist such as salbutamol be added for additional relief." The effect of combining the two agonists, however, has received little attention. Salmeterol is a partial agonist in vitro compared with salbutamol'2 and could therefore reduce the access and effectiveness of salbutamol by occupying i receptors. We studied the effect of adding increasing doses of salbutamol to salmeterol 50, 100, and 200 pg to examine the drugs' interaction and estimate dose equivalence.
Subjects and methods
We studied 12 subjects (three women) aged 18-54 years with asthma but no other medical problems. All were lifelong non-smokers, had a normal electrocardiogram, a baseline forced expiratory volume in one second (FEVy) greater than 60% predicted, and at least a 15% rise in FEV1 after 400 pg inhaled salbutamol. All were taking an inhaled short acting 12 agonist as required and nine a regular inhaled steroid. Subjects gave informed written consent and the study was approved by the Nottingham City Hospital ethics committee.
FEV, was measured by dry bellows spirometer with the subject seated and the better of two successive measurements was recorded. Heart rate, QTc interval, tremor, and plasma potassium were measured as described'°; plasma creatine kinase concentration by the N-acetyl cysteine activated method; and creatine kinase myocardial isoenzyme by immunochemical separation (Isomune-CK, Roche subject to inhale deeply three times. Measurements were taken in the same order at baseline, two hours after placebo or salmeterol, and 15 minutes after each dose of salbutamol. Symptoms were documented before each dose of drug. The study was stopped if symptoms became severe or if heart rate rose above 140 beats per minute. Patients stayed in the department until symptoms settled and heart rate had fallen below 110 beats per minute.
ANALYSIS
The study had 90% power to detect a difference in heart rate of 6 5 beats/min according to our previous study.'0 Baseline, maximum changes, and final measurements on the four study days were compared by analysis of variance with the generalised linear interactive modelling (GLIM) statistical package and expressed as means with 95% confidence intervals.
Symptoms were compared by the XI test. Dose equivalence was estimated from the salbutamol dose which caused the same effect as that seen with each dose of salmeterol. This was done by plotting each person's response to each dose of salmeterol on the log dose response curve after placebo and salbutamol for each index. Raw data were used and geometric means and 95% confidence intervals were calculated with the confidence interval analysis (CIA) statistical package. When the change with salmeterol was above the highest or below the lowest change seen with salbutamol the highest or lowest salbutamol dose was used in the analysis as a censored value.
Results
Baseline, FEVy, heart rate, plasma potassium concentration, QTc interval, tremor amplitude, and creatine kinase concentration (including myocardial isoenzyme) did not differ significantly at the four visits ( figure) .
Heart rate and tremor amplitude increased and plasma potassium concentration decreased roughly in parallel on the four study days (figure). No significant difference was found in the maximum change seen for any Change from baseline after salbutamol 40 (6) 48 (4) 50 (9) 51 (6) Tremor (cm/s'):
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Change from baseline after salbutamol 6-5 (1-8) Cumulative dose of salbutamol (puffs) Mean changefrom baseline (with standard error bars) in FEVI, heart rate, plasma potassium concentration, QTc interval, tremor amplitude, and creatine kinase myocardial isoenzyme concentration two hours after placebo (s) or salmeterol 50 og (0), 100 p.g (0), or 200 pg (0) and after the addition of increasing doses of salbutamol up to cumulative dose of3600 1sg of the measures on the four study days ( and safety of combining salmeterol and salbutamol we examined the effects ofadding salbutamol to salmeterol on the airway response and potential side effects in patients with mild asthma. Measurements were taken when maximal changes in airway and systemic responses would be expected.' 1'-1' A 200 [tg dose of salmeterol was included in addition to the recommended doses of 50 and 100 Fg to extend the dose range of salmeterol. Salmeterol caused a largely dose dependent increase in airway and systemic effects, although only salmeterol 200 Fg increased tremor amplitude and QTc interval. The addition of salbutamol caused a roughly parallel fall in plasma potassium concentration and increase in heart rate, tremor amplitude, and QTc interval confirming a largely additive effect; the dose response curves for salbutamol seemed to converge at higher doses.
Although more potent than salbutamol on human airways, salmeterol is a partial agonist achieving about 70% of the maximum effect seen with salbutamol.'2 When a partial and fuller agonist are combined the partial agonist, by occupying receptors, acts as a partial antagonist, thus reducing the effectiveness of the fuller agonist. Salmeterol could therefore reduce the efficacy of salbutamol when the two are given in combination. In vitro, the dose response curve for a fuller agonist in the presence of a partial agonist is shifted to the right with an elevated baseline and a tendency for the curves to converge and cross over with increasing dose. '6 Experiments in vitro permit maximum stimulation of ,B receptors and relaxation of smooth muscle, which are unlikely to occur in vivo. Although the suggestion of convergence of the dose response curves for salbutamol is in keeping with an interaction between an agonist and a partial agonist, our data suggest that this interaction is unlikely to be large enough to cause a clinically important reduction in beneficial or adverse effects of salbutamol in patients taking salmeterol. Such an interaction, however, remains possible in patients with severe asthma.
DOSE EQUIVALENCES
This is the first study to compare the beneficial and adverse effects of increasing doses of salmeterol and salbutamol. Single dose comparisons of salmeterol 50 pg and salbutamol 200 ptg have generally shown similar effects on FEV1, heart rate, and tremor, leading to the view that 50 Rg salmeterol is roughly equivalent to 200 jig salbutamol.' 4 One study looking at the protection provided by the two drugs against histamine induced bronchoconstriction suggested a more than fourfold difference in potency.3
Our study allowed us to. estimate dose equivalence from the dose response findings with salbutamol and salmeterol. The response to cumulative doses of salbutamol was compared with that to non-cumulative doses of salmeterol. The estimate of dose equivalence for FEV1 is probably conservative since the airway response to salbutamol is greater with cumulative doses.'7 The use of a spacing device for the higher salbutamol doses increases the amount delivered to the airways and might also underestimate dose equivalence since airway and systemic effects of 2 agonists are mainly due to inhaled drug.'5 The dose equivalence for plasma potassium concentration, tremor, and particularly FEV1 fell with increasing doses of salmeterol as would be expected if the responses were reaching a plateau. The values for the 50 and 100 jig doses of salmeterol (generally between 8 and 10) may therefore be better estimates of dose equivalence. The lower dose equivalence for QTc interval remains unexplained but may reflect compensatory mechanisms or greater P2 selectivity of salmeterol.
Salmeterol seems to be up to 10 times more potent weight for weight than salbutamol for effects on heart rate, plasma potassium, and tremor. Thus for peak effects salmeterol 50 [tg is equivalent to up to 500 [ig salbutamol. The dose equivalence over 24 hours is more difficult to estimate but since salmeterol has a longer duration of action salmeterol 50 [ig twice daily may be equivalent to salbutamol 500 [ig four to six hourly.
Our findings have two important implications. Firstly, studies comparing salmeterol 50 ,ug twice daily with salbutamol 200 pg four times a day45 are not comparing equi-effective doses and differences between the two drugs may be due to differences in dose rather than differences in drug. Secondly, high doses of , agonist are associated with an increased risk of death'9 and epidemics of death from asthma have been associated with marketing of high doses of j3 agonists.79202' Whether the relation between high doses of , agonists and mortality is causal remains uncertain but until the question is settled the high dose of salmeterol relative to salbutamol must raise some concerns. Further studies are needed to address the dose equivalence of salmeterol and the optimum dose for long term treatment.
